6 June 2022
BerGenBio ASA: BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022
Bergen, Norway, 6 June 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, is pleased to announce presentation of a poster at the ASCO Annual Meeting to be held from 3rd – 8th June 2022.
The poster presentation provides clinical data from a Phase 1 dose escalation and expansion study of bemcentinib (BGB324) in combination with docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). The data presented indicate that bemcentinib in combination with docetaxel shows evidence of anti-tumor activity, with 35% of patients achieving a partial response and 47% attaining stable disease, and a manageable safety profile in previously treated, advanced NSCLC.
Cristina Oliva, Chief Medical Officer at BerGenBio, commented: “While the data are limited, they suggest a mechanism by which treatment with bemcentinib could delay resistance to and potentiate the effects of chemotherapy treatment in NSCLC patients.”
The full abstract is available on the ASCO website here: https://meetings.asco.org/abstracts-presentations/212839
Full details of the presentation are below:
Title:Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC.
Author:Bhalla et al.
Session/Abstract ID:Lung Cancer – Non Small Cell Metastatic / 9081
Location/Time: June 6, 2022, Hall D1, 1:25pm Central Time
Contacts:
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentiallyfirst-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Suchrisks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
